Motif Bio PLC Result of General Meeting (8668F)

TIDMMTFB

RNS Number : 8668F

Motif Bio PLC

01 August 2016

Motif Bio plc

("Motif Bio" or the "Company")

Result of General Meeting

Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the General Meeting held earlier today, all resolutions were duly passed.

For further information please contact:

 
 Motif Bio plc                                                      info@motifbio.com 
  Richard Morgan (Chairman) 
  Graham Lumsden (Chief Executive 
  Officer) 
 Zeus Capital Limited (NOMAD & 
  BROKER) 
  Phil Walker/Giles Balleny 
  Dominic Wilson                                                  +44 (0)20 3829 5000 
 Northland Capital Partners Limited 
  (BROKER) 
  Patrick Claridge/ David Hignell 
  John Howes/ Rob Rees (Broking)                                  +44 (0)20 3861 6625 
 Walbrook PR Ltd. (FINANCIAL PR        +44 (0)20 7933 8780 or motifbio@walbrookpr.com 
  & IR)                                                      Mob: +44 (0)7980 541 893 
  Paul McManus                                               Mob: +44 (0)7900 608 002 
  Mike Wort 
 
 MC Services AG (EUROPEAN IR) 
 Raimund Gabriel                                                   +49 (0)89 210 2280

About Motif Bio

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an intravenous formulation of iclaprim, for the treatment of ABSSSI, which are expected to complete in the second half of 2017.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ROMUGUBURUPQGWG

(END) Dow Jones Newswires

August 01, 2016 09:15 ET (13:15 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024